234 Users Online
Sarcopenia Treatment Market Segmented By Protein Supplement, Vitamin B12 Supplement and Vitamin D and Calcium Supplement Treatment Type
The sale of vitamins, proteins, minerals, and nutritional and herbal supplements for sarcopenia treatment have surged due to the growing aging population and interest in preventive healthcare. Most of the population in the U.S., Europe, and Japan are taking supplements to stay healthy and as a cure for malnutrition-related diseases. Around 30% sale of vitamins and dietary supplement in the U.S. was to consumers aged 65 and above. Increasing adoption of supplements among the aging population due to growing health consciousness is the major factor expected to boost the demand for sarcopenia treatment and supplements.
FREE Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
The growing aging population is another major factor expected to boost the growth of the sarcopenia treatment market as the prevalence of sarcopenia is high among old age population. The global population is projected to increase over the time. People aged 65+ are the fast-growing demographics in the increasing global population. According to the National Institutes of Health (NIH), the global population of the people aged 80 and older is expected to grow from 126.5 million to 446.6 million between 2015 and 2050.
Increasing out-of-pocket healthcare expenditure is the major factor expected to boost the demand for sarcopenia treatment supplement. According to the National Health Expenditure Accounts (NHEA), the U.S. health care spending grew 4.3 percent in 2016, reaching US$ 3.3 trillion or US$ 10,348 per person
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionSarcopenia is a very common disease but there are no proper treatment options available. As the prevalence of sarcopenia is high among the older population, many manufacturers are focusing on research and development of drugs to treat sarcopenia. The companies and organizations such as Nestle, Novartis, GSK, the European Working Group on Sarcopenia in Older People (EWGSOP), and International Osteoporosis Organization are particularly focusing on research and development activities and conducting clinical trials for age-related loss of muscle mass.
Many pharmaceutical companies demonstrated positive clinical trial for drug development. For instance, in June 2017, Novartis AG announced the positive results of a 24-week randomized study of Bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. Increasing research and development activities by the manufacturer are expected to spur the opportunity for sarcopenia treatment market growth.
Most of the pharmaceutical and food-processing companies are investing in the development of new nutrition supplements in order to focus on the sarcopenia treatment. Some of the companies are investing in startups and setting up a venture with the aim of investing in the early stage nutraceuticals businesses. In Feb 2016, Nestle bought a stake in Pronutria Biosciences.
Nestle paid 42.3 million Swiss francs (US$ 42.5 million) for a "significant" stake in Pronutria. Pronutria is developing products to treat brain, metabolic, muscle and liver disorders. Pronutria will use the Nestlé cash to develop a new compound called PN-107, which has the potential to tackle muscle loss caused by aging, long bed rest or immobilization. These investments are expected to spur the growth of sarcopenia treatment market.
Sales Team
Client Partner
The micronutrient-rich foods are being consumed in low proportions in developing and underdeveloped countries, which result in malnutrition. Malnutrition is the major cause of sarcopenia. In regions such as Latin America, Africa, and Southeast Asia the prevalence of malnutrition is very high due to poor nutritional status.
Increasing malnutrition are lead to increase in sarcopenia prevalence and create high demand for sarcopenia treatment supplements. Vitamin D and Vitamin B12 deficiency are high among vegetarian and old age population which is the main cause of sarcopenia. Increasing vitamin deficiency is expected to propel the demand for sarcopenia treatment supplements.
The competition section of the sarcopenia treatment market features profiles of key players operating in the industry based on their market shares, differential strategies, product offerings marketing approaches, and company dashboard. Some of the key players featured in the report include Abbott Laboratories, Pfizer Inc., GlaxoSmithKline Plc., Nestlé S.A., Sanofi S.A., Bayer AG, Amway, Novartis AG, Cadila Healthcare Ltd., Eli Lilly and Company and other. The key manufacturers in the sarcopenia treatment market are focusing on novel marketing and sales strategies to increase their product penetration. The companies offering sarcopenia treatment supplement are focusing on online product offering and digital marketing.
There is no approved treatment option available for sarcopenia treatment but nutrition and dietary supplements have a key role in sarcopenia treatment. Major Sarcopenia treatment supplement comprises of protein, amino acids, creatine, omega 3 acid, vitamin D and B12, calcium carbonate. Nutrition prevents accelerated muscle loss during a period of muscle disuse and maintains energy.
PMR conducted a research study on sarcopenia treatment market for the forecast period of 2018 to 2026. The report offers a comprehensive evaluation of the business opportunities prevailing in the sarcopenia treatment market along with insights on the consumption trend, disease prevalence, awareness level, and market competition. The report elaborates on the macroeconomic factors influencing the dynamics of sarcopenia treatment market and its futuristic potential.
The report offers a comprehensive taxonomy of sarcopenia treatment market based on treatment type, distribution channel and region. Based on treatment type, the global sarcopenia treatment market is segmented into protein supplement, vitamin D & calcium supplement, and vitamin B12 supplement. Based on the distribution channel, the global sarcopenia treatment market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and hypermarket & supermarket. The sarcopenia treatment market has been analyzed across regions of North America, Latin America, Europe, Asia Pacific and MEA.
Some of the additional questions addressed in the report for sarcopenia treatment market-
The sarcopenia treatment market has been estimated based on sarcopenia prevalence pool and consumption of supplement. The market was first calculated based on sarcopenia prevalence percentage in different region/countries. The market value was estimated based on the treatment rate and consumption of different supplement in the top 20 countries globally.
The primary factor of market value estimation is the daily requirement of different supplement for elderly, dosage pattern, consumption rate, weighted average prices of supplement. Other qualitative factors analyzed during the value estimation includes awareness level, adoption, and others. This information is further validated with rigorous primary research (including interviews, surveys, in-person interactions, and viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals, and resourceful databases).
The research study on sarcopenia treatment market also includes top trends and macro as well as microeconomic factors shaping the sarcopenia treatment market. With this approach, the report on sarcopenia treatment market anticipates the industry attractiveness of every major segment over the forecast timespan.
